Possible reprieve for failed Alzheimer’s drug
A month after Pfizer and Janssen’s Alzheimer’s drug bapineuzumab failed in a late-stage study, a new trial has found it may benefit a sub-group of patients.
Read MoreA month after Pfizer and Janssen’s Alzheimer’s drug bapineuzumab failed in a late-stage study, a new trial has found it may benefit a sub-group of patients.
Read MoreThe new health secretary Jeremy Hunt will have a baptism of fire this month as he heads straight into negotiations over VBP.
Read MoreAndrew Lansley has been dropped as the UK health secretary just months after his controversial reform of the National Health Service became law.
Read MoreThe government will invest up to £99,000 for new projects that can help doctors and patients communicate digitally, whilst also increasing access to online information.
Read MoreMore than half a century after Thalidomide caused serious disability to hundreds of children, Grunenthal, the manufacturer for the drug has now apologised for its disastrous side effects.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479